A Phase II Trial of AK104 in Combination With Docetaxel in Subjects With Advanced Non-Small Cell Lung Cancer and Progressive Disease After Platinum Doublet Chemotherapy and Treatment With One Prior Anti-PD-1/PD-L1 Monoclonal Antibody (mAb)
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Cadonilimab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Akeso Biopharma
Most Recent Events
- 12 Mar 2025 Planned End Date changed from 20 Mar 2024 to 30 Jun 2026.
- 12 Mar 2025 Planned primary completion date changed from 20 Mar 2023 to 30 Jun 2025.
- 12 Mar 2025 Status changed from recruiting to active, no longer recruiting.